Related Experiment Video
Updated: Jul 24, 2026

16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study
N Turjanski1, A J Lees, D J Brooks
1MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
Neurology
|July 1, 1997
Summary
Posttraumatic parkinsonism (PTP) shows uniform nigrostriatal changes on 18F-dopa PET scans, differentiating it from Parkinson's disease (PD). This imaging technique aids in distinguishing PTP, a sequela of head trauma, from idiopathic PD.
Area of Science:
- Neurology
- Neuroimaging
- Nuclear Medicine
Background:
- Posttraumatic encephalopathy (PTE) encompasses diverse neurological deficits.
- A rare "striatal" variant presents with posttraumatic parkinsonism (PTP), often challenging to differentiate from idiopathic Parkinson's disease (PD).
Purpose of the Study:
- To investigate the utility of 18F-dopa Positron Emission Tomography (PET) in differentiating PTP from idiopathic PD.
- To characterize the in vivo neurochemical profile of PTP using 18F-dopa PET.
Main Methods:
- Six patients with presumed PTP underwent 18F-dopa PET scans.
- PET findings were compared with age-matched healthy controls and idiopathic PD patients.
- Quantitative analysis of 18F-dopa uptake in the caudate and putamen was performed.
Main Results:
- PTP patients exhibited a uniform 40% reduction in 18F-dopa uptake in the caudate and putamen compared to controls.
- Putamen uptake in PTP was significantly higher than in PD patients, while caudate uptake was lower.
- The caudate:putamen uptake ratio in PTP was similar to controls but significantly lower than in PD patients.
Conclusions:
- 18F-dopa PET can help distinguish PTP from idiopathic PD by revealing uniform nigrostriatal involvement in PTP.
- The findings suggest relative sparing of caudate function in PTP compared to PD.
- Delayed neurological deficits following cumulative head trauma are supported by these findings.
Related Concept Videos
Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

